

FROM:

<http://www.us.sandostatin.com/health-care-professional/index.jsp>

**Warnings and Precautions:**

*Gallbladder abnormalities may occur: Patients should be monitored periodically.*

*Glucose Metabolism: Hypoglycemia or hyperglycemia may occur. Blood glucose levels should be monitored when Sandostatin LAR Depot treatment is initiated or when the dose is altered. Antidiabetic treatment should be adjusted accordingly.*

*Thyroid Function: Hypothyroidism may occur. Baseline and periodic assessment of thyroid function (TSH, total and/or free T4) is recommended.*

*Cardiac Function: Bradycardia, arrhythmia, conduction abnormalities, and other EKG changes may occur. The relationship of these events to octreotide acetate is not established because many of these patients have underlying cardiac disease. Use with caution in at-risk patients.*

*Nutrition: Octreotide may alter absorption of dietary fats. Monitoring of vitamin B<sub>12</sub> levels is recommended during therapy with Sandostatin LAR Depot. Patients on total parenteral nutrition (TPN) and octreotide should have periodic monitoring of zinc levels.*

**Drug Interactions:** *The following drugs require monitoring and possible dose adjustment when used with Sandostatin LAR Depot: cyclosporine, insulin, oral hypoglycemic agents, beta-blockers, bromocriptine. Octreotide has been associated with alterations in nutrient absorption, so it may have an effect on absorption of orally administered drugs. Drugs mainly metabolized by CYP3A4 and which have a low therapeutic index should be used with caution.*

**Adverse Reactions:** *The most common adverse reactions occurring in patients receiving Sandostatin LAR Depot are:*

*Acromegaly:*

*biliary abnormalities (52%)*

*diarrhea (36-48%)*

*cholelithiasis (13-38%)*

*abdominal pain or discomfort (11-29%)*

*flatulence (26%)*

*influenza-like symptoms (20%)*

*constipation (19%)*

*headache (15%)*

*anemia (15%)*

*hyperglycemia (15%)*

*injection site pain (2-14%)*

*hypertension (13%)*

*dizziness (12%)*

*fatigue (11%)*  
*nausea (10%)*  
*vomiting (7%)*  
*hypothyroidism (2%)*  
*hypoglycemia (2%)*  
*goiter (2%).*  
*Carcinoid Tumors and VIPomas*  
*biliary abnormalities (62%)*  
*injection site pain (20-50%)*  
*nausea (24-41%)*  
*abdominal pain (10-35%)*  
*fatigue (8-32%)*  
*headache (16-30%)*  
*hyperglycemia (27%)*  
*back pain (8-27%)*  
*constipation or vomiting (15-21%)*  
*dizziness (18-20%)*  
*sinus bradycardia (19%)*  
*pruritus (18%)*  
*URTI (10-18%)*  
*myalgia (4-18%)*  
*flatulence (9-16%)*  
*arthropathy (8-15%)*  
*rash (15%)*  
*generalized pain (4-15%)*  
*sinusitis (5-12%)*  
*conduction abnormalities (9%)*  
*hypoglycemia (4%),*  
*arrhythmia (3%).*

## **References**

- . *Sandostatin® LAR Depot [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2010.*
- . *Data on file. Novartis Pharmaceuticals Corporation.*
- . *PubMed [database online]. National Center for Biotechnology Information. Available at: <http://www.ncbi.nlm.nih.gov/sites/gquery?term=sandostatin>. Accessed March 19, 2009.*

***How much does Sandostatin® LAR Depot cost?***

*How much the drug will cost depends on the local pharmacy where it is dispensed and what your individual insurance plan may cover. This amount can vary. If you have insurance questions about Sandostatin® LAR Depot, call **1-877-LAR-HELP***

*(1-877-527-4357) to be connected to a reimbursement specialist. He or she will help you find out more about your health plan's coverage for Sandostatin® LAR Depot and whether you would be eligible for other kinds of assistance.*

***Is patient assistance available?***

*Novartis Pharmaceuticals Corporation is committed to providing access to our medications for those most in need through the Novartis Patient Assistance Fund Inc. (PAF). PAF provides assistance to patients experiencing financial hardship who have no third party insurance coverage for their medicines. For more information, visit [www.patientassistancenow.com](http://www.patientassistancenow.com).*